These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 21452513)

  • 21. Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults.
    Pace D
    Future Microbiol; 2010 Nov; 5(11):1629-40. PubMed ID: 21133685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The challenge of post-implementation surveillance for novel meningococcal vaccines.
    Snape MD; Medini D; Halperin SA; DeTora L; Drori J; Moxon ER
    Vaccine; 2012 May; 30 Suppl 2():B67-72. PubMed ID: 22230578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Vaccinal strategies in response to new epidemiological challenges in 2010. Reasonable hope for a "B" meningococcal vaccine].
    Nicolas P
    Med Trop (Mars); 2010 Aug; 70(4):325-32. PubMed ID: 22368926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serogroup B meningococcal vaccines.
    Zimmer SM; Stephens DS
    Curr Opin Investig Drugs; 2006 Aug; 7(8):733-9. PubMed ID: 16955685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a vaccine against serogroup B has been the main scientific challenge. Preface.
    Rappuoli R; Pizza M; Black S; Moxon ER
    Vaccine; 2012 May; 30 Suppl 2():B1-2. PubMed ID: 22607893
    [No Abstract]   [Full Text] [Related]  

  • 26. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine.
    Bröker M; Veitch K
    Travel Med Infect Dis; 2010 Jan; 8(1):47-50. PubMed ID: 20188306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The implications of vaccines for prevention of bacterial meningitis.
    Riordan A
    Curr Opin Neurol; 2010 Jun; 23(3):319-24. PubMed ID: 20173637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Meningococcus B vaccine: a new tool against invasive bacteric diseases].
    Carlino C; Zaratti L; Franco E
    Ig Sanita Pubbl; 2013; 69(3):363-75. PubMed ID: 23903040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of vaccination on meningococcal epidemiology.
    Stefanelli P; Rezza G
    Hum Vaccin Immunother; 2016 Apr; 12(4):1051-5. PubMed ID: 26512927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection.
    Pace D
    Curr Opin Mol Ther; 2009 Dec; 11(6):692-706. PubMed ID: 20072946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2010 FIFA world cup South Africa: travel health issues and new options for protection against meningococcal disease.
    Zuckerman JN; Bröker M; Worth C
    Travel Med Infect Dis; 2010 Mar; 8(2):68-73. PubMed ID: 20478511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y.
    Cooper B; DeTora L; Stoddard J
    Expert Rev Vaccines; 2011 Jan; 10(1):21-33. PubMed ID: 21162617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.
    Bai X; Borrow R
    Expert Rev Vaccines; 2010 Oct; 9(10):1203-17. PubMed ID: 20923270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The epidemiology of meningococcal disease and the impact of vaccines.
    Khatami A; Pollard AJ
    Expert Rev Vaccines; 2010 Mar; 9(3):285-98. PubMed ID: 20218857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL; van den Dobbelsteen GP; de Groot R
    Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Meningococcal serogroup B vaccines].
    Dommergues MA
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S65-9. PubMed ID: 22883369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New frontiers in meningococcal vaccines.
    Anderson AS; Jansen KU; Eiden J
    Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
    El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
    Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.
    Trotter CL; Ramsay ME
    FEMS Microbiol Rev; 2007 Jan; 31(1):101-7. PubMed ID: 17168998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The threat of meningococcal disease during the Hajj and Umrah mass gatherings: A comprehensive review.
    Yezli S
    Travel Med Infect Dis; 2018; 24():51-58. PubMed ID: 29751133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.